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Abstract
Tissue healing is a complex process involving a cascade of cellular and molecular 
events that are mostly shared by the different tissues of the body. Interestingly, the 
tissue repair process initiates immediately after a traumatic injury and is mediated 
and controlled by a wide range of cytokines, proteins, and growth factors released 
from platelets upon activation. Consequently, many growth factors have been con-
sidered as therapeutic molecules for the repair or regeneration of a wide range of 
tissues. Although their role has been only partially elucidated, the potential benefit of 
most growth factors has been demonstrated. In the last few years, the development 
of platelet-rich preparations has revolutionized the field of regenerative medicine, 
due to the repair capacities of the platelet-released growth factors that stimulate and 
accelerate both soft and hard tissue healing and regeneration. Today, autologous 
platelet concentrates (APCs) are used in a wide range of disciplines such as dentistry, 
oral surgery, orthopedics, sport medicine, dermatology, and plastic and reconstruc-
tive surgery. The purpose of this chapter is to describe the current evidence regarding 
the benefits of using autologous platelet concentrates in various oral surgery proce-
dures, using a systematic review approach.
Keywords: platelet concentrates, growth factors, tissue regeneration, oral surgery
1. Introduction
Autologous platelet concentrates (APCs) have been widely used in many different clinical 
situations that require a rapid tissue healing and regeneration as it is especially the case 
in oral and maxillofacial surgery, orthopedics, sports medicine, ophthalmology, and in the 
treatment of skin ulcers. APCs are hemocomponents, obtained through centrifugation of 
patient’s own blood, in order to collect the most active blood components: platelets, fibrin, 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
and in certain cases also leukocytes. The final product has a platelet concentration higher than 
the basal level, consequently has an increased number of platelet-derived growth factors [1]. 
The rationale of the clinical use of such platelet-rich preparations is based upon the concept 
of exploiting their contents enriched of numerous mitogenic platelet-derived growth factors 
(including platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), 
endothelial growth factor (EGF), vascular endothelial growth factor (VEGF), insulin-like 
growth factor-1 (IGF-1), basic fibroblast growth factor (FGF), and hepatocyte growth factor 
(HGF)) as well as other key molecules in promoting tissue healing (as adhesive proteins, 
pro-coagulant factors, cytokines, chemokines, and anti-microbial proteins [2–5]) to stimulate 
many biological functions, such as chemotaxis, angiogenesis, proliferation, and differentia-
tion (Table 1) in order to enhance hard and soft tissue healing.
Category Term Biological activities
Adhesive proteins VWF + propeptide, Fg, Fn, Vn, TSP-1, 
and laminin-8
Cell contact interactions, clotting, and 
extracellular matrix composition
Clotting factors and associated 
proteins
F V/Va, F XI, Gas6, protein S, 
HMWK, AT, and TFPI
Thrombin production and regulation 
and angiogenesis
Fibrinolytic factors and associated 
proteins
Pgn, PAI-I, u-PAm, OSN, α2-AP, 
HRGP, TAFI, and α2-M
Plasmin production and vascular 
modeling
Proteases and antiproteases TIMP-4, MMP-4, inhibitor of FIX, 
PN-II, C1-INH, and A1AT
Angiogenesis, vascular modeling, 
regulation of coagulation, and 
regulation of cellular behavior
Growth factors, cytokines, and 
chemokines
PDGF, TGFβ-1 and -2, EGF, IGF-
1,VEGF, bFGF, FGF-2, HGF, CCL5, 
IL-8, MIP-1α, CXCL5, MCP-3, ANG-
1, and IL-1β, neutrophil chemotactic 
protein
Chemotaxis, cell proliferation and 
differentiation, and angiogenesis
Basic proteins and others PF4, β-TG, PBP, CTAP III, NAP-2, 
and ES
Regulation of angiogenesis, vascular 
modeling, and cellular interactions
Antimicrobial proteins TC Bactericidal and fungicidal properties
Others CS-4, AB, and Ig Diverse
Membrane glycoproteins αIIbβ3, αvβ3, GPIb, PECAM-1, most 
plasma membrane constituents, 
receptors for primary agonists, 
CD40L, TF, and P-selection
Platelet aggregation and 
adhesion, endocytosis of proteins, 
inflammation, thrombin generation, 
and platelet-leukocyte interactions
Extracted and readapted from Anitua et al. [2].
Table 1. Platelet α-granule contents and their functional categories.
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2. Brief history of platelet concentrates
2.1. Fibrin adhesives
More than 40 years ago, these technologies were originally used as sealant-adhesive agents 
in the treatment of hemorrhage with the aim of blocking the blood leakage [6]. Subsequently, 
other molecules involved in the coagulation process were combined to such fibrin prepara-
tions to improve their adhesive properties. These preparations were referred as “platelet-
fibrinogen-thrombin mixtures” and were successfully used in ophthalmology [7, 8], general 
surgery [9], and neurosurgery [10]. Other authors termed them as “gel foam” [11].
It is noteworthy that the application of these preparations was essentially related to their 
adhesive properties and the platelets were served only to reinforce the fibrin matrix architec-
ture. A few years later, it was developed the concept that these preparations could have heal-
ing and regenerative properties. In the late 1980s, Knighton et al. [12–14] used the autologous 
“Platelet-Derived Wound Healing Factors (PDWHF),” which were prepared through two-
step centrifugation process, in the treatment of chronic nonhealing cutaneous ulcers. In 1997, 
Whitman et al. used platelet concentrate referred as “platelet gel” in oral and maxillofacial 
surgery [15].
2.2. Platelet-rich plasma
The term “Platelet-Rich Plasma” (PRP) was, for the first time, introduced by Kingsley et al. 
to describe a thrombocyte concentrate [16] used for the treatment of severe thrombopenia. 
However, the use of PRP term really started with Marx in 1998 [1] when he published a 
comparative clinical study in which the PRP regenerative potential was demonstrated in a 
series of patients undergoing mandibular reconstruction. Afterward, the PRP product was 
associated with the concept of platelet growth factors and their potential contribution to the 
enhancement of tissue healing.
According to the PRP protocol, the blood is collected in tubes containing anticoagulants and 
processed by two centrifugation steps. Figure 1 illustrates schematically the specific protocol 
[17]. The final PRP product can be applied to the surgical site with a syringe or be activated 
by thrombin and/or calcium chloride to trigger platelet activation and to stimulate the fibrin 
polymerization.
After blood collection into tubes with anticoagulant, the first centrifugation at low force (soft 
spin) allows the separation of blood into three distinct layers: red blood cells at the bottom, a 
cellular plasma (platelet-poor plasma (PPP)) in the upper portion, and a whitish layer called 
buffy coat located between them containing the highest concentration of platelets and leuko-
cytes. For the production of Pure-PRP (P-PRP), PPP and the superficial buffy coat layer are 
transferred into another tube and centrifuged at high forces (hard spin), after which most of 
the PPP and leukocytes are discarded and the final P-PRP can be collected. For the production 
of PRP rich in leukocytes (L-PRP), PPP, the entire buffy coat layer and some residual red 
blood cells are collected and transferred in another tube to be hard spin centrifuged. To obtain 
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the final L-PRP, PPP is discarded leading to an L-PRP that contains the buffy coat with most 
of the platelets and leukocytes, some residual red blood cells and PPP (adapted from Dohan 
Ehrenfest et al. [17]).
Currently, more than 20 different commercial systems for PRP preparation exist, which may 
lead to products with different features, especially regarding the composition and the cell 
concentration rate respect to baseline. On average, a 5–8× concentration is achieved though a 
ratio of up to 11× has been reported with PRP.
2.3. Platelet-rich fibrin
In 2001, Choukroun et al. developed a protocol for producing a hemocomponent named plate-
let-rich fibrin (PRF) [18]. Here, the blood is collected in tubes in the absence of anticoagulant and 
centrifuged with moderate forces (3000 rpm in a dedicated centrifuge) for 12 min. Afterward, 
three layers are formed: red blood cells and acellular plasma are located, respectively, at the bot-
tom and at the top of the tube, and the fibrin clot, positioned between them, is PRF (Figure 2). 
Since the formation of the PRF clot naturally occurs within the tube, it has a strong fibrin matrix 
in which most of the platelets and leukocytes are embedded [19]. Since its introduction, PRF 
has undergone some development: the advanced PRF (a-PRF) was launched a few years ago, 
characterized by a reduced centrifugation speed and time (2700 rpm, 8–10 min), which allows 
a more even cell distribution within the clot [20]. Recently, the injectable PRF (i-PRF) has also 
been developed, which may be obtained with a further softer spin (1500 rpm, 3 min), consisting 
of a liquid form, very rich in white cells that can be used by infiltration into tissues and joints.
Figure 1. Protocol for PRP production.
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2.4. Plasma rich in growth factors
In parallel to the introduction of PRP and PRF, Anitua in 1999 proposed another platelet  concentrate 
protocol, denominated plasma rich in growth factors (PRGF) [21]. Briefly, blood is collected in 
tubes containing 0.2 ml of 3.8% trisodium citrate as anticoagulant. After a centrifugation at 580 g for 
8 min, red blood cells and buffy coat layer are deposited at the bottom of the tube and the plasma 
component above. The latter is then manually separated into two fractions. The lower portion of 
about 2 ml, above the buffy coat, is the PRGF, whereas the upper portion is the plasma poor in 
growth factors (PPGF) (Figure 3). The final PRGF product may be applied as a liquid fraction to the 
target site or may be preactivated by adding 0.2 ml of 10% CaCl
2
 to induce the clot formation [22].
2.5. Technical differences between PRGF, PRP, and PRF
PRGF differs from PRP for the following technical aspects:
1. Blood volume drawn is minimal (5–40 ml).
2. Requires a single centrifugation for the preparation.
3. Does not contain leukocytes.
4. Does not contain proinflammatory cytokines.
5. Platelet concentration is reduced (2–3 fold the baseline, respect to 5–8× for PRP).
In addition, PRGF also differs from PRF for these features:
1. Different products can be obtained (liquid, gel, membrane, and fibrin clot).
2. PRGF liquid can be combined with bone graft materials for bone regeneration procedure.
Differences between PRP and PRF are as follows:
1. PRP preparation requires two centrifugations.
2. Different products can be obtained (liquid and fibrin clot).
3. PRP liquid can be mixed with bone graft materials for bone regeneration procedures.
Figure 2. Protocol for PRF production. (Adapted from Dohan Ehrenfest et al. [19]).
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3. Clinical evidence of the efficacy of autologous platelet concentrates in 
oral regenerative surgical procedures
3.1. General aspects
In the last couple of decades, it has been observed a growing interest in the use of autologous 
platelet concentrates during oral regenerative surgical procedures as an adjunctive tool to 
enhance the hard and soft tissue healing. The following sections will summarize the recent 
evidence on the efficacy of autologous platelet concentrates in the dental field. The recent 
evidence has been obtained using a systematic review approach. The focused question was: 
“Does the adjunct of autologous platelet concentrate produce benefits to hard and soft tissue 
healing in oral surgery procedures in terms of tissue parameters, postoperative complications 
as well as patient’s postoperative quality of life?” In order to address the aim of this chapter, 
electronic searches were performed on the main scientific databases (MEDLINE, Scopus, and 
Cochrane Central Register of Controlled Trials). Proper search terms were used, combined by 
Boolean operators. Only controlled clinical trials, randomized clinical trials, and existing sys-
tematic reviews and meta-analyses of the literature were included. The outcomes were com-
plications and adverse events, treatment success, discomfort/quality of life, bone healing and 
remodeling assessed by histological and radiographic techniques, and soft tissue healing. The 
surgical procedures taken into consideration were: tooth extraction, periodontal surgery, end-
odontic surgery and treatment of immature necrotic teeth, maxillary sinus augmentation, and 
implant treatment. When possible, a quantitative analysis was undertaken by meta-analysis 
approach, using the software RevMan (RevMan, Version 5.3, The Nordic Cochrane Center, 
The Cochrane Collaboration, Copenhagen, Denmark, 2014).
3.2. Alveolar postextraction healing
Several recent systematic reviews evaluated the efficacy of autologous platelet concentrates in 
enhancing alveolar socket healing after tooth extraction [23, 24]. Beneficial effects were gener-
ally reported in terms of better soft tissue healing, better clinical and histological epithelializa-
tion of wound margins, and a faster wound closure, although the heterogeneity of the data 
Figure 3. Process of PRGF production. Details are given in the text. (Adapted from Anitua [22]).
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could not allow sound meta-analyses. Regarding the bone formation, the qualitative synthesis 
of the histological analyses reported a better bone quality in biopsies retrieved from sites 
treated with platelet concentrate. Furthermore, the meta-analysis of the histomorphometric 
evaluation of the bone formation (including only few of the included studies) revealed that 
sites treated with platelet concentrate showed a statistically significant greater proportion of 
new bone than the controls, at 3 months of follow-up [23]. Even though the results of the meta-
analysis suggest a beneficial effect of autologous platelet concentrates on bone formation, cau-
tion should be paid on interpreting such results, since the available evidence is scarce and of 
limited quality [23]. In spite of the relatively numerous randomized clinical studies assessing 
the value of APCs for enhancing postextraction socket healing, the main reason that prevents 
a wide meta-analysis is that the methods used for assessing bone regeneration and socket 
preservation are very different, providing different information that cannot be aggregated. 
In fact, different studies used different techniques like histological and immunohistological 
analysis, histomorphometric evaluation, scintigraphy, micro-TC, intraoral radiography, cone 
beam computed tomography, and clinical assessment, for the evaluation of different variables 
as percentage of new bone formation, osteoblasts activity, bone density, crestal bone level 
changes, ridge width and height, and soft tissues health status [23, 24]. All studies that evalu-
ated postoperative symptoms like pain, swelling, trismus, and adverse events like dry socket, 
alveolitis, and acute inflammation concluded that APCs are effective in reducing symptoms 
and the incidence of adverse events, with an overall improvement of patients’ quality of life 
[24]. The most recent systematic review on this topic concludes that APCs should be used 
in postextraction sites in order to improve clinical and radiographic outcomes such as bone 
density and soft tissue healing, as well as to reduce postoperative symptoms [24]. The actual 
benefit of APCs on decreasing of pain in extraction sockets, however, though consistently 
reported, is still not quantifiable [24]. In Figure 4, a brief sequence of pictures documenting a 
Figure 4. Double tooth extraction in the upper jaw and placement of PRGF in the extraction socket. (A) Fresh sockets 
after atraumatic extraction. (B) Sockets filled with PRGF clot; it can be sutured for a better stabilization. (C) 14 days after 
surgery: excellent healing of soft tissues is shown.
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case of double extraction in the posterior upper jaw, subsequent positioning of platelet con-
centrate (PRGF) into extraction sockets, and the postsurgical clinical healing is shown.
3.3. Periodontal defects
Several systematic reviews and some meta-analyses evaluated the efficacy of autologous 
platelet concentrates in the treatment of periodontal defects, including intrabony defects, gin-
gival recessions, and furcation defects [25–33]. Beneficial effects on clinical and radiographic 
outcomes in the treatment of infrabony defects were reported, although a high heterogeneity 
emerged among the clinical studies in terms of outcomes evaluated and bioactive agents/
procedures combined with autologous platelet concentrates [25, 28, 30–32]. Furthermore, two 
meta-analyses [28, 30] concluded that PRP might exert positive adjunctive effects in the surgi-
cal treatment of such defects when combined with grafting materials, but no adjunctive effects 
were found in association with the guided tissue regeneration technique. Indeed, the latter is 
considered the gold standard for the treatment of periodontal intrabony defects and its use 
could probably mask the PRP effect. Regarding the autologous platelet concentrates’ effect on 
gingival recessions, very few systematic reviews have been conducted, presumably due to the 
limited data about it. PRP or PRF did not show any clinical improvements in the treatment of 
gingival recessions or furcation defects [28, 33]. A Cochrane systematic review on this topic is 
still ongoing [34] and its results will certainly shed light on the actual evidence level regarding 
this topic, possibly confirming early indications of previous systematic reviews.
3.4. Endodontics and endodontic surgery
Platelet concentrates have been recently used in the clinical treatment of immature necrotic 
teeth, with the aim of regenerating the intracanal pulp and stimulating tooth development, 
as well as in the surgical treatment of teeth with apical periodontitis to enhance healing of 
periapical tissues. Clinical evidence on the benefits of the use of platelet concentrates in these 
pathologies exists but is still scarce. A recent systematic review concluded that periapical 
healing and apical closure were improved in those immature necrotic teeth treated with PRP 
compared with the control group without PRP, even though not statistically significant, and 
a significant better thickening of dentinal walls and root lengthening were also reported [35]. 
However, from the histological point of view, it seems that a true regeneration of necrotic pulp 
tissue of either mature or immature teeth was not achieved after using platelet concentrates. 
In fact, the neoformed intracanal tissues were mainly cemento-like, bone-like, and connective 
tissue. Root canals were repopulated with living tissue that only marginally resembled the 
original pulp. Despite this, the root maturation may be achieved and teeth function is not 
compromised [36].
Though the use of APCs in the management of periapical lesions could be considered a proper 
indication, very scarce studies are present regarding this topic. One randomized clinical study 
evaluated the postoperative quality of life in patients undergoing endodontic surgery [37]. 
The test group of 18 patients was treated with the adjunct of P-PRP and the control group 
was treated conventionally, without P-PRP. The test group showed significantly less pain 
and swelling, fewer analgesics taken, and improved functional activities as compared with 
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the control group [37]. This suggests that the adjunct of P-PRP to the endodontic surgery 
procedure may produce significant beneficial effect to patients’ quality of life during the early 
postoperative period.
Another pilot clinical study on endodontic surgery compared a group of seven patients 
treated with the adjunct of PRF versus four control patients [38]. In addition to confirm-
ing the beneficial effects in the early postoperative period regarding significant reduction 
of pain and swelling, a significantly better healing of the lesion was observed after 2 and 3 
months but not after 1-year follow-up [38]. This preliminary study had a very small sample 
size, so results should be interpreted cautiously. The latter two studies have been included 
in a recently published Cochrane systematic review on endodontic procedures for the 
retreatment of periapical defects, which concluded that there is evidence that adjunctive 
use of a gel of plasma rich in growth factors reduces postoperative pain compared with no 
grafting [39]. Regarding other possible beneficial effects of APCs in endodontic surgery, 
further evidence is needed.
3.5. Maxillary sinus augmentation
The use of platelet concentrates in association with grafting material during maxillary sinus 
augmentation procedure provided conflicting results in both preclinical and clinical studies 
[40, 41]. A recent meta-analysis documented that PRP combined to graft materials, in this 
type of surgical procedure, had no adjunctive effect on bone formation, on implant survival 
and implant stability as well as it did not show any statistically significant differences on 
marginal bone loss or alveolar bone height, compared to the bone graft alone [42]. Similar 
conclusions were also reported in other systematic reviews [43, 44]. However, another meta-
analysis reported opposite conclusions concerning the bone formation supporting the use 
of PRP for sinus bone graft [45]. Furthermore, beneficial effects on soft tissue healing as well 
as reduction of postoperative discomfort were often reported [43]. Such variability in results 
could be ascribed to a number of factors. First of all, different techniques have been adopted 
for the preparation of platelet concentrates, leading to the products with different characteris-
tics (final concentration of platelets and white cells, presence or absence of leukocytes, use of 
anticoagulants and activators, different mechanical consistence of the product, and associa-
tion with different graft types) and, presumably, different biological activities. Secondly, dif-
ferent studies may also differ in experimental design, objectives, outcome variables, inclusion 
criteria, and follow-up duration. Furthermore, the sinus augmentation technique, though 
representing a very popular model for the assessment of bone substitutes for bone regenera-
tion, suffers from a number of confounding factors that make standardization difficult, like 
patient age, residual bone quality and quantity, smoking habits, volume of graft used, poros-
ity and general features of the graft material (e.g., intraoral or extraoral autografts, allografts, 
xenografts, and alloplasts), graft resorbability over time, graft healing time, and intra- and 
postsurgical complications like membrane perforation, infection, expertise of the clinician, 
techniques adopted for evaluating bone formation, including the position of the biopsy 
(crestal or lateral). Finally, if one aims at evaluating the effect of APCs on implant survival 
and success in the maxillary sinus augmentation, a number of additional factors concern-
ing the implants and the prosthetic reconstruction must be considered, e.g., implant length 
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and width, shape, surface micro- and nano-geometry, type of implant-abutment connection, 
implant primary stability, and number and position of the implants. In fact, it is well known 
that implant survival in the augmented maxillary sinus is more variable than that of implants 
placed in the posterior maxilla.
A randomized clinical trial evaluating the effect of P-PRP adjunct on postoperative quality of 
life of patients undergoing maxillary sinus augmentation procedure, found a beneficial effect 
of P-PRP regarding pain, swelling, hematoma, and other postoperative symptoms, improving 
patient’s acceptance of this often demanding procedure [46].
3.6. Implant dentistry
As it is claimed that platelet concentrates may promote bone regeneration, several ani-
mal studies have been conducted to assess the PRP effect on the osseointegration process, 
through histological and histomorphometrical evaluation, but controversial results have been 
reported. In fact, some studies did not demonstrate any advantages of PRP over non-PRP 
control groups at stimulating faster bone formation or higher bone-implant contact [47–49]. 
By contrast, histomorphometric analyses of the bone-implant interface in the early healing 
phase after implantation (6 or 8 weeks) revealed a significantly higher percentage of bone-
implant contact in implants coated with liquid PRP formulation compared to those not PRP-
bioactivated [50–52]. In addition to being time dependent, PRP effect is also site dependent 
since its effect has been reported to decrease with increasing distance from the site of applica-
tion [52]. Similarly, liquid-PRP showed a tendency to increase the bone apposition to rough-
ened titanium implants during early healing phase [53, 54].
Clinical studies reported a higher bone formation around the implants [55] and a good 
preservation of the alveolar crest around postextraction implants [56, 57] when APCs 
were used.
APCs have been also combined with several different types of grafting materials during 
regenerative procedures associated with implantoprosthesis rehabilitations, showing satisfy-
ing results and positive patient-related outcomes [58–61]. A long-term clinical study (10–12 
years) on short implant placement in association with PRGF reported an implant survival rate 
of 98.9% and marginal bone loss inferior to 1 mm [62].
3.7. Systemically compromised patients
Patients affected by chronic systemic conditions like osteoporosis, cancer, diabetes type I or 
II, immunodeficiency, hematological/coagulation defects ,and other conditions, often pres-
ent difficulty in healing even after simple surgical procedures, like the extraction of a tooth. 
Therefore, the use of a safe tool that may enhance the healing process in a natural way may 
represent a remarkable benefit for these patients.
A few studies have been published on the use of platelet concentrates in systemically com-
promised patients, most of them are regarding postextraction healing. Some examples will 
be reported.
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3.8. Diabetes
In a split-mouth study in 34 patients with diabetes mellitus candidate to bilateral tooth extraction 
of a total of 127 teeth, alveolar sockets on the test side were treated with P-PRP and on the control 
side they were left to heal in a natural way [63]. The P-PRP group showed a significantly better 
healing (evaluated through the Healing Index) and a faster closure of the alveolus (by evaluation 
of the residual socket volume) at 3 and 7 days after extraction, as compared to the control group 
[63]. The authors concluded that platelet growth factors stimulate a faster epithelialization, pro-
tecting the alveolus in early healing steps. Hence, it is avoided occurrence of alveolitis, very com-
mon in diabetic patients following tooth extraction.
3.9. Irradiated patients
In a split-mouth study on 20 patients that underwent radiotherapy for head and neck cancer, 
and candidate to bilateral tooth extraction, alveolar sockets on the directly irradiated side 
were treated with P-PRP (test group) and on the untreated side they were left to heal in a 
natural way (control group) [64]. Twenty-four bilateral extractions were performed in the 
mandible and 33 in the maxilla for a total of 114 extractions. The P-PRP group showed a 
significantly better healing, in terms of Healing Index and residual socket volume at each 
follow-up (7, 14, and 21 days), as compared to the control group. Patients were followed up 
to 24 months after surgery. In the control group, two cases with bone exposure were retreated 
with P-PRP and subsequently healed [64].
3.10. Osteoradionecrosis (ORN)
In a series of 10 patients who developed osteoradionecrosis, debridement of necrotic bone 
(performed with ultrasonic instruments) was associated with the adjunct of P-PRP. All 
patients successfully healed, with no intraoperative or postoperative complications up to 12 
months of follow-up [65]. Tissue regeneration and closure was excellent, and postoperative 
pain, assessed through visual analogue score (VAS) scores, was low. In spite of the absence of 
a control group, this study suggested that P-PRP may be beneficial as an adjunct to surgical 
treatment of ORN, for predictable enhancement of tissue vascularization and epithelialization 
in patients with a history of head and neck radiotherapy.
3.11. Coagulation defects
A case-control study was performed on 66 patients affected by severe thrombocytopenia 
(<50,000 platelets/μL) and in need for at least two tooth extraction each [66]. For these patients, 
postoperative bleeding represents an important issue. Teeth were extracted in two consecutive 
interventions. In one intervention, the patients received a platelet transfusion before extrac-
tion (systemic treatment) and in the other session, the postalveolar sockets were filled with 
P-PRP (local treatment). Patients were evaluated frequently in the first 7 days after extraction. 
The group treated locally with P-PRP showed a statistically significant reduction in postop-
erative bleeding, hematoma, and need for reintervention, as compared to the group receiving 
a systemic infusion of platelets [66]. Therefore, P-PRP in postalveolar sockets may strongly 
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reduce the risk of hemorrhage and related complications in thrombocytopenic patients, due 
to the ability of stimulating healing and its hemostatic properties.
3.12. Bisphosphonate-related osteonecrosis of the jaws
Recently renamed medication-related osteonecrosis of the jaw (MRONJ), it is an adverse drug 
reaction consisting of progressive bone destruction in the maxillofacial region of patients 
under current or previous treatment with a bisphosphonate or another antiresorptive or 
antiangiogenic drug. Since APCs demonstrated to enhance bone and soft tissue healing in 
oral surgery procedures, it is reasonable to believe that they might provide benefits to these 
patients. A recent systematic review included 18 studies, reporting on 362 patients undergo-
ing oral surgery in combination with APCs [67]. The adjunct of APC in the surgical treat-
ment of necrotic bone removal significantly reduced osteonecrosis recurrence as compared 
to control (Figure 5). APC was associated with a reduced, though not significant, incidence 
of BRONJ after tooth extraction. Heterogeneity among studies was found regarding bisphos-
phonate type, clinical indication, administration route, treatment duration, triggering factors, 
study design, follow-up duration, type of APC, and outcomes adopted to evaluate treatment 
success [67]. Though the results of this review must be cautiously interpreted, since they are 
based on low evidence level studies, with limited sample size, they are suggestive of pos-
sible beneficial effects of APC when associated with surgical procedures for treatment or pre-
vention of BRONJ. To confirm such indication, prospective comparative studies with a large 
sample size are urgently needed. Another subsequent systematic review on the same topic 
substantially confirmed these results, highlighting the need for well-done evidence-based 
comparative studies [68].
3.13. Implants in patients assuming bisphosphonates
In a multicenter study on a cohort of 235 middle-aged osteoporotic women under bisphos-
phonates therapy, the outcome of a total of 1267 implants was evaluated after a minimum 
follow-up of 24 months [69]. The implants were always placed in combination with P-PRP, 
used as a coating over implant surface at insertion (Figure 6). The main outcomes (adverse 
Figure 5. (A) A case of an oncologic patient under bisphosphonate affected by osteonecrosis of the upper jaw, undergoing 
respective surgery for removal of the necrotic bone. (B) PRGF is placed within the region involved from resection. 
(C) One year after surgery, the region is completely healed.
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events) were implant failure and incidence of osteonecrosis of the jaw (ONJ). Sixteen implants 
were lost in 16 patients up to 120 months after placement, representing a survival of 98.7% on 
an implant basis and 93.2% on a patient basis [69] No cases of ONJ occurred. The results are 
perfectly in line with those of healthy patients.
Overall, the above results suggest that the use of procedures aimed at enhancing tissue heal-
ing, such as autologous platelet concentrates, may produce relevant benefits in patients at risk 
due to their compromised systemic condition and should be recommended.
4. Conclusion
The use of autologous platelet concentrates generally produced beneficial effects, though 
the level of evidence differs among various surgical procedures. In postextraction sockets 
and periodontal intrabony defects, the advantage of using APCs, both alone and combined 
with bone substitutes, is well documented by a number of randomized clinical studies. In 
maxillary sinus augmentation, controversial outcomes exist, due to few published controlled 
studies. Also, in endodontic surgery and implant treatment, there is a paucity of evidence-
based studies, even though all show beneficial effects of APC. The variability among protocols 
and outcomes in different studies often prevents the possibility of performing meta-analysis 
and is thought to be related to the controversial results sometimes observed. Better soft tis-
sue healing, improved patients’ quality of life and reduced incidence of adverse events and 
Figure 6. Multiple implant placements in an osteoporotic woman under bisphosphonates. PRGF membrane was used to 
cover the region involved from implant surgery.
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complications are systematically reported when using APC. In conclusion, the use of such 
autologous products is recommended for improving predictability and patients’ acceptance 
of treatment in oral surgery procedures.
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